Syndax Pharmaceuticals Inc - SNDX
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jul 09, 2026 | Chief Executive Officer | M | A | 32,375.0 | 0.0 | 0.0 | 0.0 | View | |
| Jul 09, 2026 | Chief Executive Officer | S | D | 32,375.0 | 24.2402 | 784,776.48 | 484,843.0 | View | |
| Jul 09, 2026 | Chief Executive Officer | M | A | 32,375.0 | 6.38 | 206,552.5 | 517,218.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | M | A | 31,235.0 | 0.0 | 0.0 | 0.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | M | A | 22,515.0 | 0.0 | 0.0 | 0.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | S | D | 31,235.0 | 18.14 | 566,602.9 | 60,885.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | M | A | 31,235.0 | 13.82 | 431,667.7 | 92,120.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | S | D | 34,280.0 | 18.0 | 617,040.0 | 60,885.0 | View | |
| Jun 12, 2026 | Head of R&D, CMO | M | A | 22,515.0 | 13.82 | 311,157.3 | 95,165.0 | View | |
| Jun 02, 2026 | Chief Financial Officer | S | D | 1,177.0 | 18.99 | 22,351.23 | 139,252.0 | View | |
| Jun 02, 2026 | Chief Executive Officer | S | D | 6,847.0 | 18.99 | 130,024.53 | 484,843.0 | View |